Drugs / PAT-1251
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02852551 | Jul → Nov 2016 | — | PharmAkea, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04054245 | Jul 2019 | myelofibrosis, primary myelofibrosis | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PAT-1251 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04054245 ↗ |
| Action | Inhibit | “LOXL2 inhibitor PAT-1251” NCT04054245 ↗ |
| Route | Oral | “PAT-1251 orally administered to healthy subjects” NCT02852551 ↗ |
| Target | LOXL2 | “LOXL2 inhibitor PAT-1251” NCT04054245 ↗ |